Article

UV-absorbing contact lenses earn commendation

Johnson & Johnson Vision Care Inc. announced that its Acuvue Advance with Hydraclear, Acuvue Advance for Astigmatism, and Acuvue Oasys with Hydraclear Plus brand contact lenses are the first contact lenses to receive the World Council of Optometry (WCO) Global Seal of Acceptance for Ultraviolet (UV) Absorbing Contact Lenses.

Boston-Johnson & Johnson Vision Care Inc. announced that its Acuvue Advance with Hydraclear, Acuvue Advance for Astigmatism, and Acuvue Oasys with Hydraclear Plus brand contact lenses are the first contact lenses to receive the World Council of Optometry (WCO) Global Seal of Acceptance for Ultraviolet (UV) Absorbing Contact Lenses. The announcement was made at the annual meeting of the American Optometric Association (AOA) in Boston.

"In awarding the Global Seal of Acceptance, the WCO Global Commission on Ophthalmic Standards [WCO GCOS]...has determined that the Acuvue Advance and Acuvue Oasys brands meet established, recognized, and accepted standards that are adopted by the WCO GCOS," said Robert Chappell, WCO president. "These include published standards of International Standards Organization [ISO] and American National Standards Institute [ANSI]."

The ISO and ANSI standards classify UV-blocking contact lenses in two groups based on the lens' absorptive capacity at its minimum thickness. Class 2 UV-blockers must absorb at least 70% of UVA and more than 95% of UVB radiation. Class 1 UV-blockers must absorb a minimum of 90% UVA and at least 99% UVB radiation. Only products that meet those standards may claim to be UV blocking. All three Acuvue lens products previously received the AOA Seal of Acceptance for UV Absorbers/Blockers.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.